Derek Jantz News Today

Powell River Salmon Society benefits from Yamaha Financial Services’ Stay Outdoors grant program via Two Wheel Tech, a local business.

Landmark approval of the first CRISPR therapy paves the way for treatments based on more efficient and more precise genome editors. Landmark approval of the first CRISPR therapy paves the way for treatments based on more efficient and more precise genome editors.

Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.

No pollen, no seeds: genome editing technique yields useful traits

NC State researchers' findings could lead to better ways of producing hybrid seeds to maximize crop productivity, or to introduce seedlessness in fruit species lacking the often-desired trait, such as raspberries, blackberries or muscadine grapes.

The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team.DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jant...

Oral and Poster Presentations to Highlight Preclinical Research for ARCUS Gene Editing Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo

Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis.

BioPharma

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) insider Derek Jantz sold 18,849 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $2.06, for a total transaction of $38,828.94. Following the sale, the insider now directly owns 4,055,174 shares of the company’s […]